Phase II study to assess the safety and efficacy of LNPP1955 in patients with psoriasis
- Registry ID
- EUCTR2016-001531-12
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Lupin Limited
- Start date
- 2016-08-16
- Completion date
- 2017-10-11
- Last update
- 2026-08-16
Conditions
- Moderate to severe plaque psoriasis
Summary
The primary objectives of the study are as follows: • To assess the POE of LNP1955 and find an optimum dose in patients with moderate-to-severe plaque psoriasis
Locations
View on source registry